PsychiatricTimes Members: Login | Register
PsychiatricTimes SearchMedica Medline Drugs

Powered by SearchMedica

 
Risk Assessment
News
Current Issues
Blogs
Special Reports
CME
Conferences
Resources
Careers
Multimedia
About Us
 

Home » Substance-Related Disorders

Psychiatric Times. Vol. 28 No. 6
Pages: 1  2  3  4  
Previous Next
SUBSTANCE ABUSE: ADDICTION & RECOVERY 

Novel Therapies for Cognitive Dysfunction Secondary to Substance Abuse

Brief Screening, Referral, and Cognitive Rehabilitation

By Antonio Verdejo-García, PhD | June 8, 2011
Dr Verdejo-García is Researcher and Lecturer at the Department of Clinical Psychology and Institute of Neuroscience, Universidad de Granada, Spain. He reports no conflicts of interest concerning the subject matter of this article.

The prevalence and durability of cognitive deficits in patients with substance use disorders raises the need to develop specific assessment and rehabilitation strategies. This is pertinent because general deficits in cognitive function and specific deficits in executive functions are robustly associated with worse drug treatment outcomes, including poorer adherence, shorter retention, and greater risk of relapse.14-16

In this article, I propose the use of a brief screening instrument for frontal-executive deficits in patients with substance use disorders and provide examples of novel treatment interventions aimed at addressing these deficits.

(MORE: Comorbid Depression and Alcohol Dependence)

Instruments to assess substance use–related cognitive deficits

Key manifestations of cognitive/executive dysfunction among patients with substance use disorders are:

• Difficulties in understanding complex instructions

• Distractibility

• Premature or disinhibited responses

• Thought and behavioral inflexibility

Some other symptoms may be neglected by the patient but stressed by significant collaterals, including problems with initiating and planning novel activities, disorganized behavior, lack of insight into his or her mistakes, and lack of concern about the consequences.

Insight is often lacking in the patient, which underscores the need for the clinician to effectively screen for cognitive dysfunction. If cognitive impairment is suspected in light of clinical observations and interviews, I recommend the use of a brief screening instrument to detect frontostriatal systems–derived cognitive, behavioral, and emotional deficits. For example, the Frontal Systems Behavior Scale (FrSBe) is a sensitive instrument used to detect frontostriatal-related deficits in patients with substance use disorders.17-19

The FrSBe is composed of 46 items (rated on a 1 to 5 Likert scale) that yield 3 scores for symptoms of apathy, disinhibition, and executive dysfunction (working memory, planning, or awareness deficits), as well as an overall score of frontostriatal-systems dysfunction. The scale includes a self-report and a collateral report. Both reports have shown adequate reliability indices, but the use of the latter is especially recommended when the patient’s insight deficits are overtly manifest.17 The scale also possesses norms extracted from the healthy population of the United States, which provides easy classification of patients as impaired or nonimpaired in comparison with demographically adjusted norms.

If the information from the clinical interviews and the scale’s scores converges to suggest at least mild cognitive impairment (below 1.5 standard deviations [SDs] in some of the FrSBe scales), the clinician can complement the assessment by administering a brief battery of neuropsychological tests focused on those cognitive abilities with well-known implications for addiction treatment prognosis (Table). Response inhibition is measured with the Stroop test, the Wisconsin Card Sorting Test (WCST) is used to measure flexibility/perseveration, decision-making capacity is measured using the Iowa Gambling Task (IGT).14-16

The Stroop test measures response inhibition, and it is based on the interference effect driven by the demand of naming the color of a word that is printed in a color incongruent with the name (eg, the word blue printed in red).20 The test consists of 3 conditions. The first condition (W) presents the words red, blue, and green printed in black ink, and patients are requested to read aloud these words. The second condition (C) presents strings of XXX printed in the same 3 colors, and patients have to name the colors as quickly and accurately as possible. The third condition (WC) introduces the interference effect: the words red, blue, and green are printed in incongruent colors and patients have to name the color and ignore the word. The interference score (IS) is calculated by subtracting a weighted mean of the first 2 conditions from the third condition [IS = WC 2 (C 3 W)/(C + W)]; then results are compared with normative values to evaluate the degree of impairment.

The WCST21 is a measure of flexibility to change. It measures response patterns in the face of changing schedules of reinforcement. The clinician presents 4 stimulus cards; the shapes on the cards differ in color, quantity, and design. The patient is given a stack of 64 cards that he has to sort according to initially unknown criteria. However, the examiner knows the criteria (the first sorting criterion is the color of the shapes, the second is the design of the shapes, and the third is the number of shapes) and provides trial-by-trial feedback of the correctness or incorrectness of each card sorted.

Patients try to sort the cards correctly by adjusting their performance to the ongoing feedback. Critically, the sorting criteria change across the test (without any overt warning from the examiner): after 10 consecutive hits in sorting by color, the criterion changes to shape, and then to number.

Pages: 1  2  3  4  
Previous Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

  • Oldest First
  • Newest First

by Richard Ash | June 16, 2011 8:24 PM EDT

I am a pancreatic cancer survivor ( 7 years ) but will have lifetime pain as the tumor was lying against the celiac sheath on the perineural nerve and had to be scraped. I take 1200 MG daily of MS-Contin ER in addition to 100MCH Fentanyl patches every three days and, 10/325 Hydrocodone for breakthough pain. I am managed by the Pain Clinic at Vanderbilt in Nashville.

I hold down a full time job of excruciating attention to detail. Creating Excel, Word and Powerpoint quotations, proposals and Statements of Work for Account Executives. ( I was an Outside Sales Rep for 25 years in Hi-Tech selling to Fortune 100 companies )

Your article on the effect of opiods on attention and other executive deficits is of interest to me as I now have to be a bit more careful in reviewing my work before submission. There is a small increment of ADD as I will spontaneously stop working to check personal emails, browse the internet on articles related to our core expertise or take a break and turn upthe volume on the wall TV in the office. I work alone, in an office outsie the home but on my property.

But, these are conscious decisions. I don't suddenly find myself away from the task at hand, rather it is a break from the tedium and, I do ( as stated ) have to be cautious about grammar and diarrhea of the keyboard.

If anyone is interested in asking me questions about my experiece you may reach me at rickash@windstream.net

Interesting work, Thank You for the posting.

Also in this Special Report

Introduction: Comorbidity, Cognition, and Pharmacotherapies

Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence

Novel Therapies for Cognitive Dysfunction Secondary to Substance Abuse

Comorbid Depression and Alcohol Dependence






 
RELATED TOPICS
Munchasuen syndrome
Substance Abuse
Opioid-related disorders
Neonatal abstinence syndrome
Cocaine-related disorders
Morphine dependence
Substance-related disorders
Substance abuse detection
Intravenous substance abuse
Eating disorders
Gambling
Trichotillomania
Physiological Sexual Dysfunction
Sexual Child Abuse
Sexual Harassment
Psychological Sexual Dysfunctions
Sexual And Gender Disorders
Social Behavior
Sex differentiation disorders
Sadism
Masochism
Internet Addiction

 


 
TOPIC INDEX

Addiction Medicine
Alzheimer Disease
Anxiety Disorders
ADHD
Bipolar Disorder
Child & Adolescent Psychiatry
Dementia
Depression
DSM-5
Geriatric Psychiatry

 

Health Care Reform
Major Depressive
Disorder
OCD
Personality Disorders
Schizoaffective Disorder
Schizophrenia
Sleep Disorders
Somatoform Disorders
All Topics

 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Developmental Psychopathology Comes of Age
  • Grief and Depression: The Sages Knew the Difference
  • The Moral Struggles of Practicing Psychiatrists
  • Update on Mental Health Benefits and Substance Use Disorder Services Under the Affordable Care Act
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Developmental Psychopathology Comes of Age
  • Psychiatry and the Myth of “Medicalization”
  • An Update on ADHD
  • Eco-Psychiatry: Why We Need to Keep the Environment in Mind
  • DSM-5: Where Do We Go From Here?
  • Suicidal Behavior: A Separate Diagnosis
  • New Insight Into the Neurobiology of Depression
  • Cultural Psychiatry and the 'No-Chicken' Doctor
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Is it Time for a Treatment Manual to Complement DSM-5?
  • Diagnosis and its Discontents: The DSM Debate Continues
  • Lamotrigine for Major Depressive Disorder Is Inappropriate
  • Psychiatry and the Myth of “Medicalization”
  • Parity Laws: Powerful Weapon—or Pipe Dream?
  • The Moral Struggles of Practicing Psychiatrists
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
  • NIMH vs DSM 5: No One Wins, Patients Lose
Click here to subscribe to our newsletter
 
CAREER CENTER

  •   Featured Jobs  
  •    Resources   
  • Psychiatry and Nurse Practitioner Opportunities
  • Associate Medical Director - Psychiatrist Delray Beach, Florida
  • Retiring Child Psychiatrist Seeks Replacement August 2010 or Before
  • Chairperson, Dept of Psychiatry Needed
  • FT Staff Psychiatrist - Excellent Benefits
  • BC Adult and Child Psychiatrits - PT and FT Positions Available
  • Managing Risks When Practicing in Three-Party Care Settings
  • 12 Tips for Making Your Practice Greener
  • Keys to Avoiding Malpractice: Standard of Care in Psychiatric Practice
  • Take This Job and Shove It
  • Merging Administrative and Academic Careers in Psychiatry
 
CME
Breaking the Cycle of Substance Abuse and Addiction: Focus on Management Strategies
Approaching Crossroads in Psychiatry: Eating Disorders, Suicide and Substance Abuse
More Addiction CME


 
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Substance Related Disorders
Evidence on Substance Related Disorders
Guidelines on Substance Related Disorders
Patient Education on Substance Related Disorders
Clinical Trials on Substance Related Disorders
Practical Articles on Substance Related Disorders
Research and Reviews on Substance Related Disorders
All "Substance Related Disorders" results

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy